JP Morgan Chase
HAE icon

JP Morgan Chase’s Haemonetics HAE Stock Holding History

JP Morgan Chase’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-35,900
Closed -$4.26M – 6174
2020
Q4 		$4.26M Buy
+35,900
New +$3.86M ﹤0.01% 2950
2020
Q3 		– Sell
-34,500
Closed -$3.09M – 5586
2020
Q2 		$3.09M Buy
+34,500
New +$3.48M ﹤0.01% 2814

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's HAE Position: Q2 2026 in Review

JP Morgan Chase reduced its Haemonetics (HAE) stake by 31% in Q2 2026, selling an estimated $6.49M and leaving 227,888 shares worth $17.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2340.

JP Morgan Chase first reported a position in HAE in Q2 2013 and has held it in 49 quarters since. The position peaked at $81.3M in Q3 2018. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • JP Morgan Chase held 227,888 shares of Haemonetics worth $17.3M as of Q2 2026.
  • JP Morgan Chase sold 101,021 Haemonetics shares in Q2 2026, an estimated $6.49M.
  • Haemonetics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2340 holding.
  • JP Morgan Chase first reported a position in Haemonetics in Q2 2013 and has held it in 49 quarters since.
  • JP Morgan Chase's Haemonetics position peaked at $81.3M in Q3 2018.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.